TMX-201 is a Imiquimod in both mouse and human mononuclear cells. TMX-201 shows less off-target binding compared to Imiquimod[1].
The maximum tolerated dose of TMX-201 by i.v. administration is 75 mg/kg[1].
TMX-201 (4mg/kg, IP) suppresses the growth of established subcutaneous B16 melanoma by 46%, without discernible adverse effects[1].
TMX-201 (IP or intra-tumor administration), in combination with anti-CTLA4 antibody, significantly suppressed lung metastasis formation in the 4T1 breast cancer model[1].
[1]. Dennis A. Carson, et al. Application of novel phospholipid conjugated Toll like receptor 7 ligands for cancer therapy by topical and systemic administration. Cancer Res 2014;74(19 Suppl): 2568.